Scientific Publications

Explore the scientific evidence for the Veracyte Diagnostics Platform, including peer-reviewed publications, conference posters, and abstracts.

Filter By

Disease Area
OR
Technology
Type
Journal/Conference
Year
Sort by

Publications

Action
Preoperative mRNA Expression Signatures Associated with 2025 American Thyroid Association (ATA) Risk of Recurrence Categories
 Afirma Thyroid
AACE
 2026 Conferences View
Molecular Characterization of Upper Pole Thyroid Nodules
 Afirma Thyroid
AACE
 2026 Conferences View
Risk of Structural Disease Recurrence Reclassification of Differentiated Thyroid Cancer from 2015 to 2025 American Thyroid Association (ATA) Guidelines
 Afirma Thyroid
AACE
 2026 Conferences View
Comparative Analysis of Nuclear Versus Other Atypia and Correlation with Histology
 Afirma Thyroid
USCAP
 2026 Conferences View
A Pilot Study of 18F-rhPSMA-7.3-PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease
 Decipher Prostate
Prostate
 2026 Discovery View
Integration of Habitat Risk Score in Radiation Therapy for Prostate Cancer
 Decipher Prostate
Int J Radiat Oncol Biol Phys
 2026 Discovery View
Impact of a Precision Medicine Navigator on Genomic Test Utilization in Black Patients With Prostate Cancer
 Decipher Prostate
JCO Oncology Practice
 2026 Utility View
Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in pts with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444)
 TrueMRD for MIBC
ASCO GU
 2026 Conferences View
Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST)
 Decipher Prostate GRID
BJU Int
 2026 Discovery View
A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity
 Decipher Bladder GRID
Eur Urol Oncol
 2026 Discovery View
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
 Decipher Bladder
Lancet Oncol
 2026 Validation, Discovery View
Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine
 Decipher Prostate
J Clin Invest
 2026 Reviews View
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer
 Decipher Bladder
Eur Urol
 2026 Validation, Discovery View
Machine learning-DeepSurv prediction model integrating mpMRI radiomics and genomic biomarkers for BCR-free survival and tumor response in prostate radiotherapy.
 Decipher Prostate
Journal of Radiation Research
 2026 Discovery View
A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer
 Decipher Prostate
Eur Urol Oncol
 2026 Validation View
A Novel Application of Decipher Testing in HoLEP Specimens for Risk Stratification of Incidentally Detected Prostate Cancer
 Decipher Prostate
Urology
 2026 Validation, Discovery View
Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes
 Decipher Prostate GRID
Eur Urol Open Sci
 2025 Discovery View
A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study
 Decipher Prostate
J Natl Compr Canc Netw
 2025 Validation View
Sociodemographic Factors Associated With Tissue-based Genomic Testing for Prostate Cancer
 Decipher Prostate
Urology
 2025 Utility View
New research presented at ATA 2024
 Afirma Thyroid
ATA
 2025 Collections, Conferences View

Showing 1–20 of 482 results

GRID Research Platform: accelerating cancer discovery through collaboration

Enabling breakthrough discoveries through our expansive curated genomic databases in cancer research.

The Genomic Resource for Intelligent Discovery (GRID) provides researchers with comprehensive whole-transcriptome databases and clinical data to accelerate cancer discoveries. Currently available for urologic and thyroid cancers, GRID enables collaborative research that advances our collective understanding of cancer biology and treatment optimization.

Explore Decipher GRID Explore Afirma GRID

Keep exploring

Veracyte Diagnostics Platform

A novel diagnostics platform helping unlock deeper cancer insights.

Discover

Clinical Studies

Studies demonstrating the impact of our tests across cancer types.

Discover

About Us

The team, our values, mission, and approach.

Learn More

Blog

Inspiring stories and latest clinical advances.

Learn More

Let’s connect

Our Medical Science Liaisons (MSLs) are field-based scientific experts equipped for in-depth discussions on our tests and how they can support your practice needs.

Contact Us